COVID-19 Vaccine Developed at UB Start-Up

Laboratory worker holding test tubes.

The science started right here at UB and is going global

Jonathan Lovell

Jonathan Lovell headshot.

Wednesday, May 12, 2021
Noon-1 p.m. EST

A COVID-19 vaccine candidate, under development by UB spinoff company POP Biotechnologies (led by UB alumni and faculty) and South Korean biotech company EuBiologics, is currently in human trials in South Korea. This could be a next-generation drug and vaccine delivery system with reach beyond the pandemic. Join Dr. Jonathan Lovell, associate professor of Biomedical Engineering, to learn more about the breakthrough and the science behind it.

“Commencing first-in-human trials is a monumental step forward for our technology. Achieving this critical milestone provides validation towards not only solving this unprecedented global crisis, but also provides invaluable support towards our platform’s development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide,” says POP Biotechnologies President Jonathan Smyth, JD '15.

About Jonathan Lovell
Dr. Jonathan F. Lovell, is the Empire Innovation Associate Professor of Biomedical Engineering at the State University of New York at Buffalo. His work has been recognized with several distinctions including the NIH Early Independence Award (2013), the Biomedical Engineering Society Young Investigator Award (2015), an NSF CAREER award (2016), the young investigator award from the Society of Porphyrins and Phthalocyanines (2018), the Basic PDT Research award from the International Photodynamic Association (2019) and the ETH Pharmaceutical Science Lectureship (2020). His research interests center around developing new tools to treat or prevent disease.